Replimune Group (NASDAQ:REPL) Insider Sells $65,956.80 in Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Konstantinos Xynos sold 7,248 shares of Replimune Group stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $65,956.80. Following the sale, the insider owned 139,685 shares of the company’s stock, valued at approximately $1,271,133.50. This trade represents a 4.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Replimune Group Stock Up 2.1%

REPL stock opened at $9.20 on Friday. The company’s 50 day moving average is $6.75 and its 200 day moving average is $7.40. The stock has a market cap of $721.65 million, a price-to-earnings ratio of -2.66 and a beta of 0.80. The company has a current ratio of 6.31, a quick ratio of 6.31 and a debt-to-equity ratio of 0.26. Replimune Group, Inc. has a 1-year low of $2.68 and a 1-year high of $17.00.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). Sell-side analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Fcpm Iii Services B.V. boosted its holdings in Replimune Group by 6.4% during the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock valued at $17,424,000 after acquiring an additional 248,672 shares during the period. Vanguard Group Inc. lifted its position in Replimune Group by 6.6% in the first quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company’s stock valued at $37,372,000 after purchasing an additional 237,185 shares during the last quarter. Braidwell LP lifted its position in Replimune Group by 550.3% in the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after purchasing an additional 2,327,205 shares during the last quarter. Balyasny Asset Management L.P. boosted its stake in shares of Replimune Group by 507.4% during the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after purchasing an additional 2,195,448 shares during the period. Finally, Readystate Asset Management LP grew its holdings in shares of Replimune Group by 1,296.2% in the third quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock worth $10,982,000 after purchasing an additional 2,433,292 shares during the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on REPL shares. Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a research note on Monday, October 20th. HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price target for the company in a research note on Monday, October 27th. Wedbush upgraded Replimune Group from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $4.00 to $18.00 in a research report on Monday, October 20th. Cantor Fitzgerald raised Replimune Group from a “neutral” rating to an “overweight” rating in a report on Wednesday, July 30th. Finally, Leerink Partnrs upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $9.75.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.